These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12948927)

  • 21. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K; Naka T; Chatani F; Yoshimura Y
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT; O'Kane KP; Jonker J; Roth J
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
    Kim S; Iwao H
    J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients.
    Rostoker G; Griuncelli M; Benmaadi A
    Ren Fail; 2006; 28(4):283-6. PubMed ID: 16771242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
    Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacological profiles of candesartan cilexetil (TCV-116)].
    Inada Y
    Nihon Rinsho; 1999 May; 57(5):1130-6. PubMed ID: 10361446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythema multiforme associated with candesartan cilexetil.
    Ejaz AA; Walsh JS; Wasiluk A
    South Med J; 2004 Jun; 97(6):614-5. PubMed ID: 15255435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
    Elmfeldt D; George M; Hübner R; Olofsson B
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM; Keating GM
    Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.
    Sever P; Holzgreve H
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S69-73. PubMed ID: 9331014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil.
    Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S29-30. PubMed ID: 9331002
    [No Abstract]   [Full Text] [Related]  

  • 36. [Angiotensin II receptor antagonists: candesartan cilexetil].
    Naka T; Kubo K; Nishikawa K; Inada Y; Furukawa Y
    Yakugaku Zasshi; 2000 Dec; 120(12):1261-75. PubMed ID: 11193378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candesartan cilexetil-induced severe hepatotoxicity.
    Basile G; Villari D; Gangemi S; Ferrara T; Accetta MG; Nicita-Mauro V
    J Clin Gastroenterol; 2003 Mar; 36(3):273-5. PubMed ID: 12590242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis.
    Johansen TL; Kjaer A
    BMC Nephrol; 2001 May; 2():1. PubMed ID: 11388887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Angiotensin II antagonist treatment as a contributory cause of acute renal failure].
    Nielsen LR
    Ugeskr Laeger; 2003 Mar; 165(13):1368-9. PubMed ID: 12703286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers.
    van Lier JJ; van Heiningen PN; Sunzel M
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S27-8. PubMed ID: 9331001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.